Drew Watson, Ph.D., MBA
 1950 Noel Drive,  Los Altos, California 94024   (650) 888-7302 
 Drew@DrewWatson.com    DrewWatson.com

Experience	
Senior VP, Biostatistics, Data Management & Medical Operations	February 2003 - Present
Genomic Health, Inc.		Redwood City, California	
Genomic Health, Inc. is an oncology-based health care services company providing individualized genomic analysis of tumor biopsies.  Management responsibilities include supervision of a group of 20 statisticians and data managers with direct reporting relationship to the Executive VP of Research and Development.  Clinical responsibilities include oversight of biostatistical data management, and medical operations activities related to the design, analysis, and regulatory submission of large-scale oncology trials in support of the development of clinical genomic tests and predictive algorithms.  Non-clinical activities include the development, validation and commercialization of high-throughput assays utilizing RNA extracted from fixed paraffin embedded tissues. 	
Founder & Chief Executive Officer	June 2001 - Present
Novation Biosciences (acquired by Agilent Technologies)		San Mateo, California	
Founder and CEO of a computational biology company aimed at lead drug discovery and quality control of high-throughput biological systems.  Raised $1.6M in Series A financing from investors including Accenture Venture Capital, Mobius Venture Capital (formerly Softbank Venture Capital), GameChange LLC, and Evercore.  Acted as Chief Scientific Officer responsible for the scientific development of the Company’s primary products including
Qualifier™ - 	a quality/performance management system for high-throughput biological systems. 
Curator™ - 	a biological text mining solution for drug discovery. 
Predictor™ - 	a lead discovery platform that utilizes both proprietary numerical, structural and semantic 	(text) data to 	predict key characteristics of lead compounds.	
VP of Quantitative Biology & General Manager of Incyte Microarray Systems	1997–2001	
Incyte Genomics		Palo Alto, California	
As General Manager, provided leadership, vision, strategic direction and operational excellence in running a division of 150 employees involved in the commercialization of gene and protein expression technologies.  Also responsible for corporate development activities including strategic and business management, technology assessment, licensing, intellectual property, and M&A activities.  Handled staffing, planning, operations, marketing and customer support activities with direct P&L responsibility for a $20M organization. As VP of Quantitative Biology provided guidance in the development of statistical, bioinformatics and quantitative methods for target identification and the analysis of genomic sequence and expression data.	
Associate Director, Biostatistics	1994–1997	
Chiron Corporation (acquired by Norvartis)		Emeryville, California	
•	Managed a biostatistical and data management department responsible for providing leadership in the discovery, development, manufacture and marketing of biopharmaceutical products including vaccines, therapeutics and molecular diagnostic devices. Clinical support responsibilities at Chiron included overseeing statistical and clinical data management activities and personnel as well as development of analysis plans, study workbooks and summary reports for the successful submission of FDA IND, NDA, 510(k) and PMA applications.  Non-clinical responsibilities involved providing biostatistical support to drug discovery, computational chemistry, bioinformatics, clinical research, assay development, process development, pharmacology, manufacturing, regulatory affairs, marketing, corporate compliance and quality assurance. 
•		
	
Manager, Experimental Statistics	1992–1994	
Syntex Pharmaceuticals (acquired by Roche Biosciences)		Palo Alto, California	
•	Provided management and statistical expertise for pharmaceutical research activities. Instrumental in the establishment of an Experimental Statistics Department responsible for R&D, pharmaceutical research, clinical development, pharmacology and assay development activities. Responsibilities included the application of statistical experimental design, optimization, robustness, reliability and statistical quality control methods for process improvement.	
Founder & Principal Management Consultant	1985–1992	
Process Plus, Inc.		Los Altos, California	
•	Founder and principal management consultant for Process Plus Inc. - a management consulting firm. Obtained over ten years’ management experience under the guidance of the late late Dr. W. Edwards Deming - “Father of the Japanese Industrial Revolution.” Consulted to industries as diverse as aerospace, biotechnology, electronics, biopharmaceutical and health care.  Clients included Hewlett-Packard (nine divisions), Dow Chemical, Applied Materials, NEC, Intel, 3-Com, Siltec, Printed Circuit Builders, Computer Products Inc., Connector Technology Inc., Conejo Circuits and Armstrong World Industries.	
Senior Statistician	1980–1985	
Hewlett-Packard Corporation		Palo Alto, California	
•	Provided management and statistical support to nine divisions, including the printed circuit and personal computer divisions.  Supported several other divisions, including the HP-3000, instrumentation and medical products divisions.  Introduced Hewlett-Packard's first quality improvement program based on the philosophies of Dr. W. Edwards Deming.  Implemented Hewlett-Packards first just-in-time manufacturing system.	

Education	
1998	Golden Gate University, Los Altos, California
MBA; G.P.A. – 4.0		
1990	University of California, Los Angeles, California
Ph.D., Biostatistics – Advisor: Robert Elashoff, Ph.D.; G.P.A. – 3.8		
1984	Stanford University, Stanford, California
M.S., Computational Statistics – Advisor: Jerome Friedman, Ph.D.; G.P.A. 3.5	 	
1980	California State University, Hayward, California
B.S., Statistics; G.P.A. – 3.5	 	

awards & Recognition	
1990	UCLA, School of Public Health, Los Angeles, California
Ruth F. Richards Award for outstanding academic achievement, character, leadership, extracurricular involvement and service to the community.	
1988	California State Superior Court, Santa Clara, California
Recognized as an expert witness in the fields of statistics and statistical quality control.	
1981	Stanford University, Department of Statistics, Stanford, California
Honors Cooperative Program: Selected by Stanford University and Hewlett-Packard Corporation to pursue graduate education at Stanford University.	
1978	Lawrence Livermore National Laboratory (LLNL), Livermore, California
Student internship in mathematical statistics.	

Publications	
Cronin M., Sangli C., Liu ML, Pho M., Dutta D., Nguyen A., Jeong J., Wu J., Langone K., Watson D., 
Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer, Paper accepted for publication, Clinical Chemistry.  	
Mina L, Soule SE, Badve S, Baehner FL, Baker J, Cronin M, Watson D, Liu ML, Sledge GW Jr, Shak S, Miller KD., Predicting Response To Primary Chemotherapy: Gene Expression Profiling Of Paraffin-Embedded Core Biopsy Tissue, Breast Cancer Research Treat. (Published ahead of print Oct 13, 2006).	
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N., Gene Expression And Benefit Of Chemotherapy In Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology. 2006 Aug 10;24(23):3726-34.	
Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. A Population-Based Study Of Tumor Gene Expression And Risk Of Breast Cancer Death Among Lymph Node-Negative Patients., Breast Cancer Research. 2006;8(3).	
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S., Gene Expression Profiles In Paraffin-Embedded Core Biopsy Tissue Predict Response To Chemotherapy In Women With Locally Advanced Breast Cancer.  Journal of Clinical Oncology. 2005 Oct 10;23(29):7265-77.	
Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN., Prognostic Role Of A Multigene Reverse Transcriptase-PCR Assay In Patients With Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy. Clinical Cancer Research. 2005 May 1;11(9):3315-9.	
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N., A Multigene Assay To Predict Recurrence Of Tamoxifen-Treated, Node-Negative Breast Cancer., New England Journal of Medicine. 2004 Dec 30;351(27):2817-26.	
Evertsz E., Gupta R., Starink P. & Watson D., Technology and Applications of Gene Expression Microarrays, Microarray Biochip Technology, BioTechniques Book Division, Eaton Publishing, Natick, Massachusetts, 2000.	
Watson G. and Minor J., Statistical Methods for Molecular Diagnostics, Proceedings of the Biopharmaceutical Section, American Statistical Association, 1997. 	
Minor J., Namini H. & Watson G., Generalized Ridge Analysis with Application to Population Pharmacokinetics/ Dynamics, Journal of Biopharmaceutical Statistics, 6(1), 105-114, 1996.	
Watson G. and Dahl T., Analysis of the Stability Properties of Drug Formulation Through the Use of Neural Networks, Proceedings of the Biopharmaceutical Section, American Statistical Association, 68-73, 1993.	
Watson G. and Elashof R., Nonparametric Influence Diagnostics for the Survivor Function, Technical Report, Department of Biomathematics, University of California, Los Angeles, CA, 1990.	
Watson G., Influential Observations in Survival Models with Censored Data, Technical Report, Department of Biomathematics, University of California, Los Angeles, CA, 1990.	

POSTERS & presentations	
Watson D, Palmer G, Baker J, Shak S., The Impact on the Recurrence Score Due to Patient Variation in the Quantitative Expression of Individual Genes or Gene Groups, Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #6039.	
Kim C, Tang G, Baehner FL, Watson D, Costantino JP, Paik S, Shak S, Wolmark N., A Comparison of Estrogen Receptor (ER) Measurement by Three Methods in Node-Negative, Estrogen Receptor (ER)-Positive Breast Cancer: Ligand Binding (LB), Immunohistochemistry (IHC), and Quantitative RT-PCR., Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #3116	
Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D., Relationship Between Proliferation Genes and Expression of Hormone and Growth Factor Receptors: Quantitative RT-PCR In 10,618 Breast Cancers. Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #6111.	
Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D., Subtypes of Breast Cancer Defined by Standardized Quantitative RT-PCR Analysis of 10,618 Tumors, Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #6118.	
Baehner FL, Habel LA, Quesenberry CP, Capra A, Tang G, Paik S, Wolmark N, Watson D, Shak S., Quantitative RT-PCR Analysis of ER and PR by Oncotype DX Indicates Distinct and Different Associations With Prognosis and Prediction of Tamoxifen Benefit, Presented at: 29th Annual San Antonio Breast Cancer Symposium. December 14-17, 2006. San Antonio, TX. Abstract #45.	
Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Clark K, Watson D., Analytical Validation For The Oncotype DX Breast Cancer Assay, a High Complexity, Multi-Analyte Molecular Diagnostic Test Service, Presented at: Association for Molecular Pathology 2006 Annual Meeting. November 16-19, 2006. Orlando, Florida. Poster #ST23.	
O'Connell MJ, Paik S, Yothers G, Costantino JP, Cowens JW, Clark KM, Baker J, Hackett J, Watson D, Wolmark N., Relationship Between Tumor Gene Expression and Recurrence in Stage II/III Colon Cancer: Quantitative RT-PCR Assay Of 757 Genes in Fixed Paraffin-Embedded (FPE) Tissue, Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, GA. Abstract #3518.	
Bitterman P, Watson D, Cronin M, Mosquera JM, Cobleigh M, Baehner R, Shak S, Baker J, Comparison Of ER, PR, HER2, And Ki-67 Quantitative Expression in Formalin-Fixed, Paraffin-Embedded Breast Carcinomas by RT-PCR with Protein Expression By Immunohistochemistry, Presented at: United States and Canadian Academy of Pathology Annual Meeting. March 6 - 12, 2004. Vancouver, British Columbia. Abstract #83.	
Cronin M, Watson D, Dutta D, Liu ML, Pho M, Baehner R, Esteban J, Baker J, Shak S, Reproducibility of Quantitative Gene Expression Analysis by a New RT-PCR Assay Using Fixed Paraffin-Embedded Tissues: A Molecular Tomographic Scanning Study, Presented at: United States and Canadian Academy of Pathology Annual Meeting. March 6 - 12, 2004. Vancouver, British Columbia. Abstract #1491.	
Mamounas E, Tang G, Bryant J, Paik S, Shak S, Costantino J, Watson D, Wickerham DL, Wolmark N., Association Between the 21-Gene Recurrence Score Assay (RS) and Risk of Loco-Regional Failure in Node-Negative, ER-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20, Presented at: 28th Annual San Antonio Breast Cancer Symposium. December 8-11, 2005. San Antonio, TX. Abstract #29.	
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner R, Walker M, Watson D, Bryant J, Wolmark N., Risk Classification of Breast Cancer Patients by the Recurrence Score Assay: Comparison to Guidelines Based On Patient Age, Tumor Size, and Tumor Grade, Presented at: 27th Annual San Antonio Breast Cancer Symposium. December 8-11, 2004. San Antonio, TX. Abstract #104.	
Future Trends for Bioinformatics Companies, Kellogg Biotechnology Conference, Sponsored by the Kellogg School 	of Management, Northwestern University, April 2001.	
cDNA Based Microarray Technology and Performance, Research Presentation, FDA/Industry Workshop on Microarray Technology, Sponsored by the Bay Area Biosciences Center, Stanford University, CA, May 17th, 2000.	
Data Mining in the Genomics Revolution, Keynote Speaker, American Statistical Association Spring 2000 Conference, Sponsored by the American Statistical Association, Wilmington, DE, April 28th, 2000.	
Statistical Methods for Molecular Diagnostics, Invited Speaker, Joint Meetings of the American Statistical Association, Anaheim, CA, August 11th, 1997. 	
Strategies of Research, Invited Speaker, Genentech Inc., Sponsored by the San Francisco Chapter of the American 	Statistical Association, San Francisco, CA, April, 1995.	

Patents	
US Patent : Tissue Specific Genes of Diagnostic Import.
US Patent Application 60/375,251:  Microarray Performance Management System.
U.S. Provisional patent Application Serial No. 60/810,077: Gene Expression Markers for Colorectal Cancer	

computer skills	
Packages: 	SAS, S-Plus, R, BMDP, SPSS, IMSL, GAUSS, LISP-Stat, GLIM, Mathematica, BMDS, StatXact, LogXact, 				Egret, East, ECHIP, Design-Ease, Statistica, SAS JMP, Resampling Stats, Maple, CART, MARS, Minitab, 				Spotfire
Languages: FORTRAN, C/C++, Visual Basic, SQL
Operating Systems: VAX/VMS, UNIX, MS-DOS, Mac, Windows	

Security clearances	
Department of Energy (D.O.E) “Q” (currently inactive).